These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 25299498)

  • 1. Lead extraction: The road to successful cardiac resynchronization therapy.
    Maciąg A; Syska P; Sterliński M; Przybylski A; Sitkowska E; Oręziak A; Bilińska M; Kuśmierczyk M; Szwed H
    Cardiol J; 2015; 22(2):188-93. PubMed ID: 25299498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complications of permanent cardiac pacing in patients with persistent left superior vena cava.
    Polewczyk A; Kutarski A; Czekajska-Chehab E; Adamczyk P; Boczar K; Polewczyk M; Janion M
    Cardiol J; 2014; 21(2):128-37. PubMed ID: 24526508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rate, causes, and impact on patient outcome of implantable device complications requiring surgical revision: large population survey from two centres in Italy.
    Palmisano P; Accogli M; Zaccaria M; Luzzi G; Nacci F; Anaclerio M; Favale S
    Europace; 2013 Apr; 15(4):531-40. PubMed ID: 23407627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased late complex device infections are determined by cardiac resynchronization therapy-defibrillator infection.
    Unsworth JD; Zaidi A; Hargreaves MR
    Europace; 2015 Nov; 17(11):1708-11. PubMed ID: 25883081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complications in recipients of cardioverter-defibrillator or cardiac resynchronization therapy: Insights from Silesian Center Defibrillator registry.
    Tajstra M; Gadula-Gacek E; Kurek A; Adamowicz-Czoch E; Olszowski D; Ostręga M; Ciślak A; Pyka Ł; Hawranek M; Lekston A; Poloński L; Gąsior M
    Cardiol J; 2017; 24(5):515-522. PubMed ID: 27734455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High recurrence of device-related adverse events following transvenous lead extraction procedure in patients with cardiac resynchronization devices.
    Regoli F; Bongiorni MG; Rordorf R; Santamaria M; Klersy C; Segreti L; De Regibus V; Moccetti T; Conte G; Caputo ML; Auricchio A
    Eur J Heart Fail; 2016 Oct; 18(10):1270-1277. PubMed ID: 27170594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes in cardiac resynchronization therapy-defibrillator recipients 80 years of age and older.
    Adelstein EC; Liu J; Jain S; Schwartzman D; Althouse AD; Wang NC; Gorcsan J; Saba S
    Europace; 2016 Mar; 18(3):420-7. PubMed ID: 26487669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of inappropriate anti-tachycardia pacing therapies and shocks by a novel suite of detection algorithms in heart failure patients with cardiac resynchronization therapy defibrillators: a historical comparison of a prospective database.
    Lunati M; Proclemer A; Boriani G; Landolina M; Locati E; Rordorf R; Daleffe E; Ricci RP; Catanzariti D; Tomasi L; Gulizia M; Baccillieri MS; Molon G; Gasparini M;
    Europace; 2016 Sep; 18(9):1391-8. PubMed ID: 26826135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implantation feasibility, procedure-related adverse events and lead performance during 1-year follow-up in patients undergoing triple-site cardiac resynchronization therapy: a substudy of TRUST CRT randomized trial.
    Lenarczyk R; Kowalski O; Sredniawa B; Pruszkowska-Skrzep P; Mazurek M; Jędrzejczyk-Patej E; Woźniak A; Pluta S; Głowacki J; Kalarus Z
    J Cardiovasc Electrophysiol; 2012 Nov; 23(11):1228-36. PubMed ID: 22651239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation of QRS Duration to Clinical Benefit of Cardiac Resynchronization Therapy in Mild Heart Failure Patients Without Left Bundle Branch Block: The Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy Substudy.
    Biton Y; Kutyifa V; Cygankiewicz I; Goldenberg I; Klein H; McNitt S; Polonsky B; Ruwald AC; Ruwald MH; Moss AJ; Zareba W
    Circ Heart Fail; 2016 Feb; 9(2):e002667. PubMed ID: 26823498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Battery longevity in cardiac resynchronization therapy implantable cardioverter defibrillators.
    Alam MB; Munir MB; Rattan R; Flanigan S; Adelstein E; Jain S; Saba S
    Europace; 2014 Feb; 16(2):246-51. PubMed ID: 24099864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of Anatomically Designed Quadripolar Left Ventricular Leads: Results from the NAVIGATE X4 Clinical Trial.
    Mittal S; Nair D; Padanilam BJ; Ciuffo A; Gupta N; Gallagher P; Goldner B; Hammill EF; Wold N; Stein K; Burke M
    J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1199-1205. PubMed ID: 27434039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PR interval identifies clinical response in patients with non-left bundle branch block: a Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy substudy.
    Kutyifa V; Stockburger M; Daubert JP; Holmqvist F; Olshansky B; Schuger C; Klein H; Goldenberg I; Brenyo A; McNitt S; Merkely B; Zareba W; Moss AJ
    Circ Arrhythm Electrophysiol; 2014 Aug; 7(4):645-51. PubMed ID: 24963007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can we rely on machines? Device-detected atrial high rates correspond well with atrial arrhythmias in cardiac resynchronization recipients.
    Jędrzejczyk-Patej E; Lenarczyk R; Mazurek M; Liberska A; Przybylska-Siedlecka K; Podolecki T; Kowalczyk J; Sokal A; Leopold-Jadczyk A; Kowalski O; Kalarus Z
    Europace; 2016 Mar; 18(3):436-44. PubMed ID: 26017467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atrial fibrillation in cardiac resynchronization therapy with a defibrillator: a risk factor for mortality, appropriate and inappropriate shocks.
    van Boven N; Theuns D; Bogaard K; Ruiter J; Kimman G; Berman L; VAN DER Ploeg T; Kardys I; Umans V
    J Cardiovasc Electrophysiol; 2013 Oct; 24(10):1116-22. PubMed ID: 23889733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac resynchronization therapy in women versus men: observational comparative effectiveness study from the National Cardiovascular Data Registry.
    Zusterzeel R; Spatz ES; Curtis JP; Sanders WE; Selzman KA; Piña IL; Bao H; Ponirakis A; Varosy PD; Masoudi FA; Caños DA; Strauss DG
    Circ Cardiovasc Qual Outcomes; 2015 Mar; 8(2 Suppl 1):S4-11. PubMed ID: 25714821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and Costs Related to Lead Damage Occurring Within the First Year After a Cardiac Implantable Electronic Device Replacement Procedure.
    Nichols CI; Vose JG; Mittal S
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of functional Sprint Fidelis leads at cardiac resynchronization therapy-defibrillator generator replacement: a novel option for preventing inappropriate shocks from lead failure in fragile patients with high risk of sudden death.
    Zhu DWX; Chu MM; House CM
    Europace; 2017 Dec; 19(12):2007-2014. PubMed ID: 27940933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epicardial leads in adult cardiac resynchronization therapy recipients: a study on lead performance, durability, and safety.
    Buiten MS; van der Heijden AC; Klautz RJM; Schalij MJ; van Erven L
    Heart Rhythm; 2015 Mar; 12(3):533-539. PubMed ID: 25460170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of cardiac resynchronization therapy combined with implantable cardioverter defibrillator for heart failure: a meta-analysis of 5674 patients.
    Chen S; Ling Z; Kiuchi MG; Yin Y; Krucoff MW
    Europace; 2013 Jul; 15(7):992-1001. PubMed ID: 23419662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.